The Parkinson's-Reversing Breakthrough

What is Parkinsons Disease

Get Instant Access

Bankiewicz KS, Eberling JL, Kohutnicka M, et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 2000; 164(1):2-14. Azzouz M, Martin-Rendon E, Barber RD, et al. Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J Neurosci 2002; 22(23):10,302-10,312.

204. Bjorklund A, Kirik D, Rosenblad C, et al. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res 2000; 886(1-2): 82-98.

205. Kordower JH, Emborg ME, Bloch J, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000; 290(5492):767-773.

206. Torres EM, Monville C, Lowenstein PR, et al. Delivery of sonic hedgehog or glial derived neurotrophic factor to dopamine-rich grafts in a rat model of Parkinson's disease using adenoviral vectors increased yield of dopamine cells is dependent on embryonic donor age. Brain Res Bull 2005; 68(1-2):31-41.

207. During MJ, Kaplitt MG, Stern MB, et al. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum Gene Ther 2001; 12(12):1589-1591.

208. Bilen J, Bonini NM. Drosophia as a model for human neurodegenerative disease. Ann Rev Genet 2005; 39:153-171.

209. Coulom H, Birman S. Chronic exposure to rotenone models sporadic Parkinson's disease in Drosophila melanogaster. J Neurosci 2004; 24(48):10,993-10,998.

210. Feany MB, Bender WW. A Drosophila model of Parkinson's disease. Nature 2000; 404(6776):394-398.

211. Pendleton RG, Parvez F, Sayed M, et al. Effects of pharmacological agents upon a transgenic model of Parkinson's disease in Drosophila melanogaster. J Pharmacol Exp Ther 2002; 300(1):91-96.

212. Auluck PK, Chan HY, Trojanowski JQ, et al. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. Science 2002; 295(5556):865-868.

213. Pesah Y, Burgess H, Middlebrooks B, et al. Whole-mount analysis reveals normal numbers of dopaminergic neurons following misexpression of alpha-synuclein in Drosophila. Genesis 2005; 41(4):154-159.

214. Greene JC, Whitworth AJ, Kuo I, et al. Mitochondrial pathology and apoptotic muscle degeneration in Drosophila parkin mutants. Proc Natl Acad Sci USA 2003; 100(7): 4078-4083.

215. Pesah Y, Pham T, Burgess H, et al. Drosophila parkin mutants have decreased mass and cell size and increased sensitivity to oxygen radical stress. Development 2004; 131(9):2183-2194.

216. Park J, Kim SY, Cha GH, et al. Drosophila DJ-1 mutants show oxidative stress-sensitive locomotive dysfunction. Gene 2005; 361:133-139.

217. Menzies FM, Yenisetti SC, Min KT. Roles of Drosophila DJ-1 in survival of dopaminergic neurons and oxidative stress. Curr Biol 2005; 15(17):1578-1582.

218. Meulener M, Whitworth AJ, Armstrong-Gold CE, et al. Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinson's disease. Curr Biol 2006; 15(17):1572-1577.

219. Moore DJ, Dawson VL, Dawson TM. Lessons from Drosophila models of DJ-1 deficiency. Sci Aging Knowledge Environ 2006; 2006(2):pe2.

220. Ghorayeb I, Puschban Z, Fernagut PO, et al. Simultaneous intrastriatal 6-hydroxydopamine and quinolinic acid injection: a model of early-stage striatonigral degeneration. Exp Neurol 2001; 167(1):133-147.

221. Wenning GK, Granata R, Puschban Z, et al. Neural transplantation in animal models of multiple system atrophy: a review. J Neural Transm Suppl 1999; 55:103-113.

222. Scherfler C, Puschban Z, Ghorayeb I, et al. Complex motor disturbances in a sequential double lesion rat model of striatonigral degeneration (multiple system atrophy). Neu-rosci 2000; 99(1):42-54.

223. Ghorayeb I, Fernagut PO, Aubert I, et al. Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration. Mov Disord 2000; 15(3):531-536.

224. Neumann M, Muller V, Gorner K, et al. Pathological properties of the Parkinson's disease-associated protein DJ-1 in alpha-synucleinopathies and tauopathies: relevance for multiple system atrophy and Pick's disease. Acta Neuropathol (Berl) 2004; 107(6): 489-496.

225. Barbieri S, Hofele K, Wiederhold KH, et al. Mouse models of alpha-synucleinopathy and Lewy pathology. Alpha-synuclein expression in transgenic mice. Adv Exp Med Biol 2001; 487:147-167.

226. Ishihara T, Hong M, Zhang B, et al. Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron 1999; 24(3):751-762.

227. Wittmann CW, Wszolek MF, Shulman JM, et al. Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 2001; 293(5530):711-714.

Was this article helpful?

0 0

Post a comment